Skip to Main Content

Paper Details

Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.
Blood
1
2024
AML, IKAROS, IKAROS protein, IKZF1, KMT2A, KMT2A-r, KMT2A-r AML, KMT2A-r and NPM1c AML, KMT2A-r and NPM1c AML cell lines, MEN1, MEN1 mutations, MENIN, MLL1, Menin, Mezigdomide, NPM1c, NPM1c AML, VTP-50469, acute myeloid leukemia, cell lines, iberdomide, lenalidomide, lysine, lysine methyltransferase 2A, mezigdomide, nucleophosmin mutant, patient, patient derived xenograft, patients
Author NameAffiliation
Yana PikmanDana Farber Cancer Institute
Gerard M McGeehanSyndax Pharmaceuticals, Inc.
Brian D CromptonDana Farber Cancer Institute
Scott A ArmstrongBoston Children's Hospital
Scott A ArmstrongBoston Children's Hospital
  • 1 - 5

Datasets

Release 1.2